Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Terrain Minerals

    MCap

    AUD13m

    Last close

    AUD0.00

    ▲ 0.00 (33.33%)

    Percheron Therapeutics

    MCap

    AUD9m

    Last close

    AUD0.01

    ▲ 0.00 (25.00%)

    Corero Network Security

    MCap

    GBP53m

    Last close

    GBP0.10

    ▲ 1.75 (20.59%)

  • Sectors

    Sectors

    View All Sectors
  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE Immunotherapeutics (PAR: OSE) – VEL-101 moves into Phase II in kidney transplantation
Published by Arron Aatkar, PhD

OSE Immunotherapeutics has announced that partner Veloxis has dosed the first patient in RENGEVITY-201, a Phase II trial of pegrizeprument (VEL-101) for the prevention of rejection in de novo kidney transplant recipients, marking the OSE-originated asset’s progression into mid-stage development. The randomised, multicentre study will enrol up to 120 patients and compare two doses of pegrizeprument with tacrolimus, alongside background immunosuppression, with primary objectives assessing safety, pharmacokinetics and pharmacodynamics. Pegrizeprument, a differentiated CD28-targeting immunomodulator licensed to Veloxis for all transplant indications, remains under Veloxis’ responsibility for worldwide development and commercialisation; while no new financial milestone was disclosed, the Phase II start represents encouraging further validation of OSE’s partnered pipeline.

Next Sparks Commentary in this sector >

Latest

TMT | Comment

Corero Network Security (AIM: CNS) – Growth accelerates; beat expected for FY26

TMT | Comment

Pathos Communications (AIM: NEWS) – Evidence the H2 acceleration is materialising

Healthcare | Comment

BioVersys (SIX: BIOV) reports strong H126; FY26 guidance upgraded

Healthcare | Comment

Newron Pharmaceuticals (SIX: NWRN) improves funding visibility ahead of pivotal readout

Industrials | Comment

Jersey Electricity (LSE: JEL) – Refinancing increases funding flexibility for £180m investment programme
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.